Mouse Genome Informatics
cn
    Nphs2tm1Antc/Nphs2tm3.1Antc
Tg(CAG-cre/Esr1*)86Lbgn/0

involves: 129 * C57BL/6 * DBA
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
       
mortality/aging
• mice die 11 weeks after tamoxifen treatment

renal/urinary system
• after 4 weeks of tamoxifen treatment, mice develop nonselective proteinuria compared with control mice
• after 2 weeks of nursing from mice fed tamoxifen
• after 10 days of tamoxifen treatment
• after 9 weeks, tamoxifen-treated mice exhibit progressive tubular injury with basement membrane thickening and interstitial fibrosis unlike similarly treated wild-type mice
• tamoxifen-treated mice exhibit focal effacement at 1 and 2 weeks then diffuse effacement at 4 weeks unlike similarly treated wild-type mice
• after 2 weeks of tamoxifen treatment, mice exhibit podocyte hypertrophy compared with similarly treated control mice
• after 4 weeks, tamoxifen-treated mice exhibit glomerular pseudocrescents in some glomeruli unlike in similarly treated control mice
• mice nursed by dams fed tamoxifen exhibit lesions of mesangial proliferation compared with similarly treated controls
• after 2 weeks of tamoxifen treatment, mice exhibit minimal mesangial matrix expansion compared with similarly treated control mice
• after 4 weeks of tamoxifen treatment, mice exhibit focal segmental glomerulosclerosis in many glomeruli with varying severity unlike in similarly treated control mice
• mice nursed by dams fed tamoxifen exhibit lesions of focal segmental glomerulosclerosis unlike similarly treated control mice
• glomerulosclerosis worsens by 6 weeks of tamoxifen treatment
• at or near death, tamoxifen-treated mice exhibit global scelrosis
• after 9 weeks in tamoxifen-treated mice
• tamoxifen-treated mice exhibit tubulointerstitial injury with diffuse tubular dilation, tubular atrophy and necrosis, and proteinaceous casts unlike in similarly treated control mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice

homeostasis/metabolism
• after 6 weeks of tamoxifen treatment
• after 6 weeks of tamoxifen treatment
• after 4 weeks of tamoxifen treatment
• after 4 weeks of tamoxifen treatment, mice develop nonselective proteinuria compared with control mice
• after 10 days of tamoxifen treatment
• after 2 weeks of nursing from mice fed tamoxifen

cardiovascular system
• modestly after 4 weeks of tamoxifen treatment

Mouse Models of Human Disease
OMIM IDRef(s)
Nephrotic Syndrome, Type 2; NPHS2 600995 J:166320